> top > docs > PubMed:10945643 > annotations

PubMed:10945643 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 13-17 PR:Q8FYW3 denotes pure
T2 13-17 PR:Q54QE4 denotes pure
T3 13-17 PR:P52558 denotes pure
T4 13-17 PR:P0AG18 denotes pure
T6 13-17 PR:000023640 denotes pure
T5 13-17 GO:0034023 denotes pure
T7 18-30 D020847 denotes antiestrogen
T8 18-30 D020847 denotes antiestrogen
T9 18-30 CHEBI:50751 denotes antiestrogen
T10 34-43 GO:0097194 denotes apoptosis
T11 34-43 GO:0006915 denotes apoptosis
T12 48-61 UBERON:2000098 denotes proliferation
T13 69-74 D006801 denotes human
T14 75-81 UBERON:0000310 denotes breast
T17 82-106 D002285 denotes ductal carcinoma in situ
T18 82-106 D002285 denotes ductal carcinoma in situ
T23 117-129 D020847 denotes antiestrogen
T24 117-129 D020847 denotes antiestrogen
T25 117-129 CHEBI:50751 denotes antiestrogen
T28 180-204 D002285 denotes ductal carcinoma in situ
T29 180-204 D002285 denotes ductal carcinoma in situ
T35 206-210 CVCL_5552 denotes DCIS
T34 206-210 D002285 denotes DCIS
T36 206-210 D002285 denotes DCIS
T38 236-240 CVCL_5552 denotes DCIS
T37 236-240 D002285 denotes DCIS
T39 236-240 D002285 denotes DCIS
T40 264-272 D004967 denotes estrogen
T41 264-272 D004967 denotes estrogen
T42 264-272 CHEBI:50114 denotes estrogen
T43 264-281 Q9PVZ9 denotes estrogen receptor
T44 264-281 Q9YHT3 denotes estrogen receptor
T45 264-281 P57717 denotes estrogen receptor
T46 264-281 Q9QZJ5 denotes estrogen receptor
T47 264-281 Q29040 denotes estrogen receptor
T48 264-281 P49886 denotes estrogen receptor
T49 264-281 P50240 denotes estrogen receptor
T50 264-281 Q91424 denotes estrogen receptor
T51 264-281 Q9YHZ7 denotes estrogen receptor
T52 264-281 P06211 denotes estrogen receptor
T53 264-281 P16058 denotes estrogen receptor
T54 264-281 P50242 denotes estrogen receptor
T55 264-281 Q53AD2 denotes estrogen receptor
T56 264-281 P49885 denotes estrogen receptor
T57 264-281 P49884 denotes estrogen receptor
T58 264-281 P19785 denotes estrogen receptor
T59 264-281 Q91250 denotes estrogen receptor
T60 264-281 P81559 denotes estrogen receptor
T61 264-281 Q9TV98 denotes estrogen receptor
T62 264-281 PR:000007204 denotes estrogen receptor
T63 264-281 Q9YH33 denotes estrogen receptor
T64 264-281 P50241 denotes estrogen receptor
T65 264-281 P06212 denotes estrogen receptor
T66 264-281 P03372 denotes estrogen receptor
T67 264-281 O42132 denotes estrogen receptor
T68 264-281 P57753 denotes estrogen receptor
T69 385-394 GO:0097194 denotes apoptosis
T70 385-394 GO:0006915 denotes apoptosis
T71 413-431 GO:0008283 denotes cell proliferation
T72 418-431 UBERON:2000098 denotes proliferation
T73 471-475 PR:Q8FYW3 denotes pure
T74 471-475 PR:Q54QE4 denotes pure
T75 471-475 PR:P52558 denotes pure
T76 471-475 PR:P0AG18 denotes pure
T78 471-475 PR:000023640 denotes pure
T77 471-475 GO:0034023 denotes pure
T79 492-501 GO:0097194 denotes apoptosis
T80 492-501 GO:0006915 denotes apoptosis
T81 506-519 UBERON:2000098 denotes proliferation
T82 523-528 D006801 denotes human
T84 529-533 CVCL_5552 denotes DCIS
T83 529-533 D002285 denotes DCIS
T85 529-533 D002285 denotes DCIS
T87 602-620 D002114 denotes microcalcification
T88 602-620 D002114 denotes microcalcification
T90 635-639 CVCL_5552 denotes DCIS
T89 635-639 D002285 denotes DCIS
T91 635-639 D002285 denotes DCIS
T92 715-721 UBERON:0000479 denotes tissue
T93 803-809 UBERON:0003100 denotes female
T94 823-827 PR:000005054 denotes mice
T96 823-827 O89094 denotes mice
T95 823-827 D051379 denotes mice
T97 823-827 10095 denotes mice
T98 846-851 10090 denotes mouse
T99 846-851 D051379 denotes mouse
T100 991-995 PR:000005054 denotes mice
T102 991-995 O89094 denotes mice
T101 991-995 D051379 denotes mice
T103 991-995 10095 denotes mice
T104 1058-1067 SO:0000667 denotes insertion
T105 1088-1093 B3TPQ7 denotes mg 17
T106 1091-1107 D004958 denotes 17beta-estradiol
T107 1091-1107 CHEBI:16469 denotes 17beta-estradiol
T108 1091-1107 D004958 denotes 17beta-estradiol
T115 1098-1107 4083 denotes estradiol
T117 1108-1114 UBERON:0036018 denotes pellet
T118 1150-1154 PR:Q8FYW3 denotes pure
T119 1150-1154 PR:Q54QE4 denotes pure
T120 1150-1154 PR:P52558 denotes pure
T121 1150-1154 PR:P0AG18 denotes pure
T123 1150-1154 PR:000023640 denotes pure
T122 1150-1154 GO:0034023 denotes pure
T126 1158-1166 203870 denotes Faslodex
T124 1158-1166 CHEBI:31638 denotes Faslodex
T125 1158-1166 D000077267 denotes Faslodex
T127 1158-1166 D000077267 denotes Faslodex
T128 1175-1190 D004364 denotes Pharmaceuticals
T129 1175-1190 CHEBI:52217 denotes Pharmaceuticals
T130 1327-1332 10090 denotes mouse
T131 1327-1332 D051379 denotes mouse
T133 1366-1370 CVCL_5552 denotes DCIS
T132 1366-1370 D002285 denotes DCIS
T134 1366-1370 D002285 denotes DCIS
T135 1415-1435 GO:0006915 denotes apoptotic cell death
T137 1463-1481 GO:0008283 denotes cell proliferation
T138 1468-1481 UBERON:2000098 denotes proliferation
T139 1528-1541 UBERON:2000098 denotes proliferation
T140 1542-1549 D000941 denotes antigen
T141 1542-1549 CHEBI:59132 denotes antigen
T142 1542-1549 D000941 denotes antigen
T144 1615-1619 CVCL_5552 denotes DCIS
T143 1615-1619 D002285 denotes DCIS
T145 1615-1619 D002285 denotes DCIS
T147 1648-1652 CVCL_5552 denotes DCIS
T146 1648-1652 D002285 denotes DCIS
T148 1648-1652 D002285 denotes DCIS
T150 1761-1765 CVCL_5552 denotes DCIS
T149 1761-1765 D002285 denotes DCIS
T151 1761-1765 D002285 denotes DCIS
T152 1811-1827 D004958 denotes 17beta-estradiol
T153 1811-1827 CHEBI:16469 denotes 17beta-estradiol
T154 1811-1827 D004958 denotes 17beta-estradiol
T161 1818-1827 4083 denotes estradiol
T166 1913-1922 4083 denotes estradiol
T163 1913-1922 CHEBI:16469 denotes estradiol
T164 1913-1922 CHEBI:23965 denotes estradiol
T165 1913-1922 D004958 denotes estradiol
T167 1913-1922 D004958 denotes estradiol
T168 1932-1944 D020847 denotes antiestrogen
T169 1932-1944 D020847 denotes antiestrogen
T170 1932-1944 CHEBI:50751 denotes antiestrogen
T171 2082-2086 PR:000005054 denotes mice
T173 2082-2086 O89094 denotes mice
T172 2082-2086 D051379 denotes mice
T174 2082-2086 10095 denotes mice
T176 2099-2103 CVCL_5552 denotes DCIS
T175 2099-2103 D002285 denotes DCIS
T177 2099-2103 D002285 denotes DCIS
T178 2120-2136 D004958 denotes 17beta-estradiol
T179 2120-2136 CHEBI:16469 denotes 17beta-estradiol
T180 2120-2136 D004958 denotes 17beta-estradiol
T187 2127-2136 4083 denotes estradiol
T189 2153-2158 PR:P03875 denotes AI (1
T191 2267-2271 CVCL_5552 denotes DCIS
T190 2267-2271 D002285 denotes DCIS
T192 2267-2271 D002285 denotes DCIS
T193 2298-2311 UBERON:2000098 denotes proliferation
T194 2335-2344 GO:0097194 denotes apoptosis
T195 2335-2344 GO:0006915 denotes apoptosis
T196 2453-2461 D004967 denotes estrogen
T197 2453-2461 D004967 denotes estrogen
T198 2453-2461 CHEBI:50114 denotes estrogen
T199 2453-2470 Q9PVZ9 denotes estrogen receptor
T200 2453-2470 Q9YHT3 denotes estrogen receptor
T201 2453-2470 P57717 denotes estrogen receptor
T202 2453-2470 Q9QZJ5 denotes estrogen receptor
T203 2453-2470 Q29040 denotes estrogen receptor
T204 2453-2470 P49886 denotes estrogen receptor
T205 2453-2470 P50240 denotes estrogen receptor
T206 2453-2470 Q91424 denotes estrogen receptor
T207 2453-2470 Q9YHZ7 denotes estrogen receptor
T208 2453-2470 P06211 denotes estrogen receptor
T209 2453-2470 P16058 denotes estrogen receptor
T210 2453-2470 P50242 denotes estrogen receptor
T211 2453-2470 Q53AD2 denotes estrogen receptor
T212 2453-2470 P49885 denotes estrogen receptor
T213 2453-2470 P49884 denotes estrogen receptor
T214 2453-2470 P19785 denotes estrogen receptor
T215 2453-2470 Q91250 denotes estrogen receptor
T216 2453-2470 P81559 denotes estrogen receptor
T217 2453-2470 Q9TV98 denotes estrogen receptor
T218 2453-2470 PR:000007204 denotes estrogen receptor
T219 2453-2470 Q9YH33 denotes estrogen receptor
T220 2453-2470 P50241 denotes estrogen receptor
T221 2453-2470 P06212 denotes estrogen receptor
T222 2453-2470 P03372 denotes estrogen receptor
T223 2453-2470 O42132 denotes estrogen receptor
T224 2453-2470 P57753 denotes estrogen receptor
T226 2480-2484 CVCL_5552 denotes DCIS
T225 2480-2484 D002285 denotes DCIS
T227 2480-2484 D002285 denotes DCIS

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-107 DRI_Background denotes Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.
T2 108-212 DRI_Background denotes Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS).
T3 213-349 DRI_Background denotes However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment.
T4 350-568 DRI_Background denotes Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and proliferation in human DCIS xenografts using an in vivo model.
T5 569-809 DRI_Approach denotes Women (n = 23) with mammographic microcalcification suggestive of DCIS were identified at the time of surgery (day 0), a sample of representative tissue was obtained, divided into multiple 2x2x1-mm xenografts, and implanted s.c. into female
T6 810-822 Token_Label.OUTSIDE denotes BALB/c nu/nu
T7 823-853 DRI_Approach denotes mice (eight xenografts/mouse).
T8 854-921 DRI_Background denotes Day 0 grafts underwent immunohistochemical assessment of ER status.
T9 922-1085 DRI_Unspecified denotes Fourteen days after implantation, four xenografts were retrieved and mice were randomly divided into one of three treatment groups: (a) insertion of a slow release
T10 1086-1107 Token_Label.OUTSIDE denotes 2-mg 17beta-estradiol
T11 1108-1243 DRI_Unspecified denotes pellet; (b) weekly 5-mg injections of the pure AE Faslodex (Zeneca Pharmaceuticals); and (c) injections of a control vehicle oil alone.
T12 1244-1333 DRI_Background denotes After 2 weeks of treatment, the remaining four xenografts were retrieved from each mouse.
T13 1334-1554 DRI_Background denotes Retrieved xenografts containing DCIS were assessed for morphological evidence of apoptotic cell death [apoptotic index (AI)] and cell proliferation (by immunohistochemical detection of the Ki67 proliferation antigen LI).
T14 1555-1732 DRI_Outcome denotes Both AI and LI were higher in the day 0 specimens of 16 ER- DCIS lesions compared with 7 ER+ DCIS lesions (mean values, 1.47% versus 0.32% and 20.6% versus 3.1%; both P<0.0001).
T15 1733-2055 DRI_Unspecified denotes AI and LI values within ER- DCIS did not differ between xenografts exposed to 17beta-estradiol or AE treatment compared with the controls or pretreatment values (mean AI and LI in estradiol-treated, antiestrogen-treated, and control groups 1.04% versus 0.98% versus 1.29% and 17.2% versus 20.5% versus 17.7% respectively).
T16 2056-2248 DRI_Background denotes In contrast, treatment of mice bearing ER+ DCIS xenografts with 17beta-estradiol raised both the AI (1.03% versus 0.40%, P = 0.03) and LI (11.0% versus 5.1%, P = 0.007) compared with controls.
T17 2249-2404 DRI_Background denotes AE therapy of ER+ DCIS xenografts did not affect proliferation but resulted in higher apoptosis than in controls (0.9% versus 0.4% respectively, P = 0.04).
T18 2405-2485 DRI_Outcome denotes AE therapy should be reserved for patients with estrogen receptor positive DCIS.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 108-212 DRI_Background denotes Adjuvant antiestrogen (AE) therapy has been proposed for all women with ductal carcinoma in situ (DCIS).
T2 213-349 DRI_Background denotes However, many cases of DCIS are of the high-grade, estrogen receptor (ER)-negative subtype that are unlikely to respond to AE treatment.
T3 350-568 DRI_Background denotes Hormonal agents work by increasing apoptosis and/or decreasing cell proliferation; therefore, we studied the effect of a pure AE on levels of apoptosis and proliferation in human DCIS xenografts using an in vivo model.
T4 569-809 DRI_Approach denotes Women (n = 23) with mammographic microcalcification suggestive of DCIS were identified at the time of surgery (day 0), a sample of representative tissue was obtained, divided into multiple 2x2x1-mm xenografts, and implanted s.c. into female
T5 823-853 DRI_Approach denotes mice (eight xenografts/mouse).
T6 854-921 DRI_Background denotes Day 0 grafts underwent immunohistochemical assessment of ER status.
T7 1244-1333 DRI_Background denotes After 2 weeks of treatment, the remaining four xenografts were retrieved from each mouse.
T8 1334-1554 DRI_Background denotes Retrieved xenografts containing DCIS were assessed for morphological evidence of apoptotic cell death [apoptotic index (AI)] and cell proliferation (by immunohistochemical detection of the Ki67 proliferation antigen LI).
T9 1555-1732 DRI_Outcome denotes Both AI and LI were higher in the day 0 specimens of 16 ER- DCIS lesions compared with 7 ER+ DCIS lesions (mean values, 1.47% versus 0.32% and 20.6% versus 3.1%; both P<0.0001).
T10 2056-2248 DRI_Background denotes In contrast, treatment of mice bearing ER+ DCIS xenografts with 17beta-estradiol raised both the AI (1.03% versus 0.40%, P = 0.03) and LI (11.0% versus 5.1%, P = 0.007) compared with controls.
T11 2249-2404 DRI_Background denotes AE therapy of ER+ DCIS xenografts did not affect proliferation but resulted in higher apoptosis than in controls (0.9% versus 0.4% respectively, P = 0.04).
T12 2405-2485 DRI_Outcome denotes AE therapy should be reserved for patients with estrogen receptor positive DCIS.